Michael J Rosen, MD, MSCI
@DrRosenIBD
Followers
3K
Following
6K
Statuses
3K
Stanford U. Endowed Professor for Pediatric IBD & Celiac Disease | Director, SMCH Center for IBD & Celiac Disease | Physician Scientist | Father & Husband
Palo Alto, CA
Joined April 2015
RT @DrsMeena: #HappyRetractionDay! Today @TheLancet retracted the fraudulent article saying vaccines cause autism. Since then, we've had hu…
0
15
0
RT @darbysaxbe: A personal story about how the potential grant funding freeze might affect science. Right now, I'm in my fourth year of a 5…
0
869
0
RT @EdBarnesMD: Check out these (hopefully) helpful tips on pouchoscopy. Knowing landmarks and having a standardized approach helps us all…
0
19
0
RT @Joseph_C_Wu: Please join @StanfordCVI seminar Tue 1/28 at 12pm PST by Dr. Bernhard Kuhn from @WCMpeds @WeillCornell @weillinstitute spe…
0
10
0
RT @DrsMeena: A reminder: The $47B NIH budget generates ~$93B in economic activity each year. There isn't another govt program that generat…
0
11
0
RT @IBDimmunology: #CCCongress25 @CrohnsColitisFn @AmerGastroAssn coming up @DrRiehl @ibdgijami @tinahamd @EdelblumLab all leading programs…
0
2
0
RT @DrJideOjo: The lab is open and we are hiring! A postdoc position is available immediately to study environmental exposures in inflamm…
0
48
0
RT @StanfordQoLA: Join our growing Quality of Life (#StanfordQoLA🐨) & Pediatric Palliative Care Division at @StanfordMed! Don't delay, appl…
0
1
0
These therapeutics target disease driving proteins and bring them to the lysosome for degradation. They don’t just block therapeutic targets; they destroy them using the body’s own machinery. Huge implication for IBD and autoimmune diseases!
The unique pharmacology of targeted degraders (eg PROTACs) leverages their sub-stoichiometric “catalytic” activity. Now @LyciaTx reports catalytic (cata)LYTACs for potent, durable extracellular TPD, cleared IgE in NHPs, superior to omalizumab 👏
0
0
2
RT @NehaSantucciMD: Thank you @NGMJournal for publishing this important study on #sleepdisturbances in #pedDGBI @NASPGHAN @ANMSociety @Cinc…
0
5
0
Thank you to Jason Shapiro for the invitation to present @HasbroChildrens and @BrownPediatrics Grand Rounds this morning on Optimizing today's and shaping tomorrow's IBD therapy for children. It was a privilege to share our work with this outstanding department!
0
0
4
Congrats to @SMCH_IBD_Celiac faculty @patelperseus and @vivicality on their publication in @AGA_GHAdvances showing how AI LLMs can be used to accurately identify IBD symptoms in 2 EMRs from separate institutions!
0
3
10
0
0
1
RT @ColmanMD: Great. Now is the time to approve vedolizumab in pediatrics (…which would be 11 years after it was first approved for adults…
0
3
0
0
2
0